{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:20:40Z","timestamp":1791404440380,"version":"4.3.3"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.intimp.2023.109714","type":"journal-article","created":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T12:59:53Z","timestamp":1673960393000},"page":"109714","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["4-Iodo-6-phenylpyrimidine (4-IPP) suppresses fibroblast-like synoviocyte- mediated inflammation and joint destruction associated with rheumatoid arthritis"],"prefix":"10.1016","volume":"115","author":[{"given":"Weiwei","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinquan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyi","family":"Nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxing","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2100-3046","authenticated-orcid":false,"given":"Youhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.intimp.2023.109714_b0005","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41584-020-0413-5","article-title":"Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes","volume":"16","author":"Nygaard","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2023.109714_b0010","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.0105-2896.2009.00854.x","article-title":"Fibroblast-like synoviocytes in inflammatory arthritis pathology: the emerging role of cadherin-11","volume":"233","author":"Chang","year":"2010","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.intimp.2023.109714_b0015","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7150\/thno.37200","article-title":"ASIC1a induces synovial inflammation via the Ca(2+)\/NFATc3\/ RANTES pathway","volume":"10","author":"Zhang","year":"2020","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.intimp.2023.109714_b0020","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nrrheum.2012.190","article-title":"Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors","volume":"9","author":"Bottini","year":"2013","journal-title":"Nat. Rev. Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2023.109714_b0025","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.0105-2896.2009.00859.x","article-title":"Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis","volume":"233","author":"Bartok","year":"2010","journal-title":"Immunol. Rev."},{"issue":"10","key":"10.1016\/j.intimp.2023.109714_b0030","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00109-006-0089-6","article-title":"Short-term hyperthermia prevents activation of proinflammatory genes in fibroblast-like synoviocytes by blocking the activation of the transcription factor NF-kappaB","volume":"84","author":"Markovic","year":"2006","journal-title":"J. Mol. Med. (Berl)"},{"issue":"6","key":"10.1016\/j.intimp.2023.109714_b0035","first-page":"1038","article-title":"Activation of synovial cell p38 MAP kinase by macrophage migration inhibitory factor","volume":"31","author":"Santos","year":"2004","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.intimp.2023.109714_b0040","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.molimm.2018.05.024","article-title":"A novel diindolylmethane analog, 1,1-bis(3'-indolyl)-1-(p-chlorophenyl) methane, inhibits the tumor necrosis factor-induced inflammatory response in primary murine synovial fibroblasts through a Nurr1-dependent mechanism","volume":"101","author":"Afzali","year":"2018","journal-title":"Mol. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2023.109714_b0045","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1002\/1529-0131(199908)42:8<1601::AID-ANR6>3.0.CO;2-B","article-title":"Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids","volume":"42","author":"Leech","year":"1999","journal-title":"Arthritis Rheum."},{"issue":"18","key":"10.1016\/j.intimp.2023.109714_b0050","doi-asserted-by":"crossref","first-page":"7253","DOI":"10.1158\/0008-5472.CAN-07-6227","article-title":"A novel, macrophage migration inhibitory factor suicide substrate inhibits motility and growth of lung cancer cells","volume":"68","author":"Winner","year":"2008","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.intimp.2023.109714_b0055","doi-asserted-by":"crossref","first-page":"7667","DOI":"10.1096\/fj.201802364RR","article-title":"Macrophage migration inhibitory factor (MIF) inhibitor 4-IPP suppresses osteoclast formation and promotes osteoblast differentiation through the inhibition of the NF-kappaB signaling pathway","volume":"33","author":"Zheng","year":"2019","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.intimp.2023.109714_b0060","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3892\/ijo.2013.1944","article-title":"Pharmacological inhibition of macrophage migration inhibitory factor interferes with the proliferation and invasiveness of squamous carcinoma cells","volume":"43","author":"Kindt","year":"2013","journal-title":"Int. J. Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2023.109714_b0065","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1530\/ERC-15-0299","article-title":"4-IPP, a selective MIF inhibitor, causes mitotic catastrophe in thyroid carcinomas","volume":"22","author":"Varinelli","year":"2015","journal-title":"Endocr. Relat. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2023.109714_b0070","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12974-019-1468-6","article-title":"Macrophage migration inhibitory factor facilitates prostaglandin E2 production of astrocytes to tune inflammatory milieu following spinal cord injury","volume":"16","author":"Zhang","year":"2019","journal-title":"J. Neuroinflammation"},{"issue":"11","key":"10.1016\/j.intimp.2023.109714_b0075","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1002\/1529-0131(200011)43:11<2501::AID-ANR18>3.0.CO;2-K","article-title":"Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis","volume":"43","author":"Schett","year":"2000","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.intimp.2023.109714_b0080","doi-asserted-by":"crossref","first-page":"e23709","DOI":"10.1002\/jcla.23709","article-title":"JNK pathway-associated phosphatase associates with rheumatoid arthritis risk, disease activity, and its longitudinal elevation relates to etanercept treatment response","volume":"35","author":"Sun","year":"2021","journal-title":"J. Clin. Lab. Anal."},{"issue":"10","key":"10.1016\/j.intimp.2023.109714_b0085","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1002\/art.22869","article-title":"Central role of the MEK\/ERK MAP kinase pathway in a mouse model of rheumatoid arthritis: potential proinflammatory mechanisms","volume":"56","author":"Thiel","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2023.109714_b0090","doi-asserted-by":"crossref","first-page":"2580207","DOI":"10.1155\/2019\/2580207","article-title":"Berberine Modulates LPA Function to Inhibit the Proliferation and Inflammation of FLS-RA via p38\/ERK MAPK Pathway Mediated by LPA1","volume":"2019","author":"Wang","year":"2019","journal-title":"Evid. Based Complement. Alternat. Med."},{"issue":"5","key":"10.1016\/j.intimp.2023.109714_b0095","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/jep.12399","article-title":"Quality of life and drug compliance: their interrelationship in rheumatic patients","volume":"21","author":"Hromadkova","year":"2015","journal-title":"J. Eval. Clin. Pract."},{"key":"10.1016\/j.intimp.2023.109714_b0100","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41413-019-0067-6","article-title":"Iguratimod: a valuable remedy from the Asia Pacific region for ameliorating autoimmune diseases and protecting bone physiology","volume":"7","author":"Li","year":"2019","journal-title":"Bone Res."},{"issue":"1","key":"10.1016\/j.intimp.2023.109714_b0105","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/ard.2006.067827","article-title":"Leflunomide and methotrexate reduce levels of activated matrix metalloproteinases in complexes with alpha2 macroglobulin in serum of rheumatoid arthritis patients","volume":"67","author":"Tchetverikov","year":"2008","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.intimp.2023.109714_b0110","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1002\/art.38652","article-title":"Effect of methotrexate use and erythrocyte methotrexate polyglutamate on glycosylated hemoglobin in rheumatoid arthritis","volume":"66","author":"de Rotte","year":"2014","journal-title":"Arthritis Rheumatol."},{"issue":"3","key":"10.1016\/j.intimp.2023.109714_b0115","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/jcph.1336","article-title":"Canadian Pharmacogenomics Network for Drug Safety, Analyses of Adverse Drug Reactions-Nationwide Active Surveillance Network: Canadian Pharmacogenomics Network for Drug Safety Database","volume":"59","author":"Tanoshima","year":"2019","journal-title":"J. Clin. Pharmacol."},{"issue":"11","key":"10.1016\/j.intimp.2023.109714_b0120","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/FPC.0000000000000085","article-title":"Genetic polymorphisms affect efficacy and adverse drug reactions of DMARDs in rheumatoid arthritis","volume":"24","author":"Zhang","year":"2014","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.intimp.2023.109714_b0125","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jconrel.2017.02.032","article-title":"Nanotherapeutics relieve rheumatoid arthritis","volume":"252","author":"Yang","year":"2017","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.intimp.2023.109714_b0130","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1080\/10717544.2018.1447050","article-title":"Targeted delivery of hyaluronic acid-coated solid lipid nanoparticles for rheumatoid arthritis therapy","volume":"25","author":"Zhou","year":"2018","journal-title":"Drug Deliv."},{"issue":"1","key":"10.1016\/j.intimp.2023.109714_b0135","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/nano8010042","article-title":"Lipid-Based Nanoparticles as a Potential Delivery Approach in the Treatment of Rheumatoid Arthritis","volume":"8","author":"Chuang","year":"2018","journal-title":"Nanomaterials (Basel)"},{"issue":"2","key":"10.1016\/j.intimp.2023.109714_b0140","doi-asserted-by":"crossref","first-page":"517","DOI":"10.7314\/APJCP.2014.15.2.517","article-title":"PLGA-based nanoparticles as cancer drug delivery systems","volume":"15","author":"Tabatabaei Mirakabad","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"23","key":"10.1016\/j.intimp.2023.109714_b0145","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1016\/S0142-9612(00)00115-0","article-title":"The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices","volume":"21","author":"Jain","year":"2000","journal-title":"Biomaterials"},{"issue":"10","key":"10.1016\/j.intimp.2023.109714_b0150","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1021\/acsbiomaterials.8b00552","article-title":"Bilayered PLGA\/PLGA-HAp Composite Scaffold for Osteochondral Tissue Engineering and Tissue Regeneration","volume":"4","author":"Liang","year":"2018","journal-title":"ACS Biomater Sci. Eng."},{"issue":"1\u20132","key":"10.1016\/j.intimp.2023.109714_b0155","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijpharm.2018.09.063","article-title":"Ketoprofen and MicroRNA-124 Co-loaded poly (lactic-co-glycolic acid) microspheres inhibit progression of Adjuvant-induced arthritis in rats","volume":"552","author":"Yu","year":"2018","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.intimp.2023.109714_b0160","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4155\/tde-2020-0113","article-title":"Engineering microenvironment of biodegradable polyester systems for drug stability and release control","volume":"12","author":"Khaliq","year":"2021","journal-title":"Ther. Deliv."},{"issue":"9","key":"10.1016\/j.intimp.2023.109714_b0165","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/14728222.2019.1656718","article-title":"Macrophage migration inhibitory factor (MIF) as a therapeutic target for rheumatoid arthritis and systemic lupus erythematosus","volume":"23","author":"Bilsborrow","year":"2019","journal-title":"Expert Opin. Ther. Targets"},{"issue":"6","key":"10.1016\/j.intimp.2023.109714_b0170","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/1529-0131(200106)44:6<1273::AID-ART219>3.0.CO;2-8","article-title":"Regulation of synoviocyte phospholipase A2 and cyclooxygenase 2 by macrophage migration inhibitory factor","volume":"44","author":"Sampey","year":"2001","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.intimp.2023.109714_b0175","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1365-2249.2008.03639.x","article-title":"Reduced arthritis in MIF deficient mice is associated with reduced T cell activation: down-regulation of ERK MAP kinase phosphorylation","volume":"152","author":"Santos","year":"2008","journal-title":"Clin. Exp. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2023.109714_b0180","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1002\/art.11165","article-title":"Regulation of p53 by macrophage migration inhibitory factor in inflammatory arthritis","volume":"48","author":"Leech","year":"2003","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.intimp.2023.109714_b0185","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.cyto.2004.02.007","article-title":"Inhibition of joint inflammation and destruction induced by anti-type II collagen antibody\/lipopolysaccharide (LPS)-induced arthritis in mice due to deletion of macrophage migration inhibitory factor (MIF)","volume":"26","author":"Ichiyama","year":"2004","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2023.109714_b0190","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0065-2776(08)60537-4","article-title":"CD44 and its interaction with extracellular matrix","volume":"54","author":"Lesley","year":"1993","journal-title":"Adv. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2023.109714_b0195","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrm1004","article-title":"CD44: from adhesion molecules to signalling regulators","volume":"4","author":"Ponta","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"49","key":"10.1016\/j.intimp.2023.109714_b0200","doi-asserted-by":"crossref","first-page":"E7917","DOI":"10.1073\/pnas.1612717113","article-title":"MIF allele-dependent regulation of the MIF coreceptor CD44 and role in rheumatoid arthritis","volume":"113","author":"Yoo","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"14","key":"10.1016\/j.intimp.2023.109714_b0205","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.2174\/1381612023394674","article-title":"Macrophage migration inhibitory factor and the discovery of tautomerase inhibitors","volume":"8","author":"Orita","year":"2002","journal-title":"Curr. Pharm. Des."},{"issue":"28","key":"10.1016\/j.intimp.2023.109714_b0210","doi-asserted-by":"crossref","first-page":"24976","DOI":"10.1074\/jbc.M203220200","article-title":"The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents","volume":"277","author":"Lubetsky","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2023.109714_b0215","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jneuroim.2018.06.009","article-title":"Contribution of the macrophage migration inhibitory factor superfamily of cytokines in the pathogenesis of preclinical and human multiple sclerosis: In silico and in vivo evidences","volume":"322","author":"Fagone","year":"2018","journal-title":"J. Neuroimmunol."},{"issue":"41","key":"10.1016\/j.intimp.2023.109714_b0220","doi-asserted-by":"crossref","first-page":"29910","DOI":"10.1074\/jbc.M704898200","article-title":"Regulation of human lung adenocarcinoma cell migration and invasion by macrophage migration inhibitory factor","volume":"282","author":"Rendon","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.intimp.2023.109714_b0225","doi-asserted-by":"crossref","first-page":"8730","DOI":"10.4049\/jimmunol.177.12.8730","article-title":"Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells","volume":"177","author":"Meyer-Siegler","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2023.109714_b0230","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1186\/s12885-015-1855-z","article-title":"Macrophage migration inhibitory factor - a therapeutic target in gallbladder cancer","volume":"15","author":"Subbannayya","year":"2015","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2023.109714_b0235","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1124\/jpet.108.137992","article-title":"Lipopolysaccharide induces macrophage migration via prostaglandin D(2) and prostaglandin E(2)","volume":"326","author":"Tajima","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"9","key":"10.1016\/j.intimp.2023.109714_b0240","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.4049\/jimmunol.1602072","article-title":"The Induction of Pro-IL-1beta by Lipopolysaccharide Requires Endogenous Prostaglandin E2 Production","volume":"198","author":"Zaslona","year":"2017","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2023.109714_b0245","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/jcb.10332","article-title":"Gene therapy and tissue engineering in repair of the musculoskeletal system","volume":"88","author":"Wu","year":"2003","journal-title":"J. Cell. Biochem."},{"issue":"1","key":"10.1016\/j.intimp.2023.109714_b0250","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1196\/annals.1402.065","article-title":"Gene therapy in musculoskeletal repair","volume":"1117","author":"Nixon","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"14","key":"10.1016\/j.intimp.2023.109714_b0255","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1016\/j.biomaterials.2010.01.116","article-title":"Polycation\/DNA complexes coated with oligonucleotides for gene delivery","volume":"31","author":"Chung","year":"2010","journal-title":"Biomaterials"},{"issue":"7291","key":"10.1016\/j.intimp.2023.109714_b0260","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature08956","article-title":"Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles","volume":"464","author":"Davis","year":"2010","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.intimp.2023.109714_b0265","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/jphp.12134","article-title":"Size-dependent internalisation of folate-decorated nanoparticles via the pathways of clathrin and caveolae-mediated endocytosis in ARPE-19 cells","volume":"66","author":"Langston Suen","year":"2014","journal-title":"J. Pharm. Pharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2023.109714_b0270","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","article-title":"PLGA-based nanoparticles: an overview of biomedical applications","volume":"161","author":"Danhier","year":"2012","journal-title":"J. Control. Release"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923000371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923000371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T14:11:32Z","timestamp":1736431892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923000371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":54,"alternative-id":["S1567576923000371"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.109714","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"4-Iodo-6-phenylpyrimidine (4-IPP) suppresses fibroblast-like synoviocyte- mediated inflammation and joint destruction associated with rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.109714","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109714"}}